SYNH

Syneos Health, Inc. Class A Common Stock

SYNH

Market cap $4.46B

Overview Fund Activity

Delisted

SYNH was delisted on the 27th of September, 2023.

Back to rankings

About: Syneos is a global contract research and outsourced commercialization organization that provides services to pharmaceutical and biotechnology firms. Its clinical solutions segment offers early- to late-stage clinical trial support that ranges from specialized staffing models to strategic partnerships that oversee nearly all aspects of a drug program, while the company's commercialization solutions includes outsourced sales, consulting, public relations, and advertising services.

Employees: 29,395

Healthcare Diagnostics & Research

Financial journalist opinion

Syneos Health Appoints Costa Panagos as Chief Executive Officer

Colin Shannon Appointed Executive Chairman Seasoned Executive Further Strengthens Company's Leadership Team MORRISVILLE, N.C., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Syneos Health®, a leading fully integrated biopharmaceutical solutions organization, today announced the appointment of Costa Panagos as CEO and a member of the Company's Board of Directors, effective immediately.

Syneos Health Appoints Costa Panagos as Chief Executive Officer

Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE®

Press Release Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE ®  Crossject expanding market access activities in preparation for filing for marketing authorization ZEPIZURE®, previously known as ZENEO® Midazolam, is separately contracted with BARDA for U.S. advanced regulatory development and specific supply to the Strategic National Stockpile Dijon, France, January 4, 2024, 18:00 CET -- Crossject (ISIN: FR0011716265; uronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations, has engaged Syneos Health, a leading fully integrated biopharmaceutical solutions organization, to prepare for the commercial launch of Crossject's ZEPIZURE® innovative rescue therapy for epileptic seizures in the U.S. Under the agreement, Syneos Health will provide support in all pre-launch and launch activities for ZEPIZURE®. Syneos Health brings a strong U.S. presence and significant expertise in commercializing new therapies for Crossject.

Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE®

See News Rankings

Charts implemented using Lightweight Charts™